A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

MLA

Phillips, Patrick P. J., et al. “A New Trial Design to Accelerate Tuberculosis Drug Development: The Phase IIC Selection Trial with Extended Post-Treatment Follow-up (STEP).” BMC Medicine, vol. 14, Mar. 2016, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12916-016-0597-3.

APA

Phillips, P. P. J., Dooley, K. E., Gillespie, S. H., Heinrich, N., Stout, J. E., Nahid, P., Diacon, A. H., Aarnoutse, R. E., Kibiki, G. S., Boeree, M. J., & Hoelscher, M. (2016). A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Medicine, 14, 1–11. https://doi.org/10.1186/s12916-016-0597-3

Chicago

Phillips, Patrick P. J., Kelly E. Dooley, Stephen H. Gillespie, Norbert Heinrich, Jason E. Stout, Payam Nahid, Andreas H. Diacon, et al. 2016. “A New Trial Design to Accelerate Tuberculosis Drug Development: The Phase IIC Selection Trial with Extended Post-Treatment Follow-up (STEP).” BMC Medicine 14 (March): 1–11. doi:10.1186/s12916-016-0597-3.